Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Psoriasis 1Plaque, Amyloid 1Lymphoma, Follicular 1Bronchiolitis Obliterans Syndrome 1

Interventions

ibrutinib 9tofacitinib 7Imatinib Mesylate 5ruxolitinib 4ofatumumab 4Rituximab 4Dasatinib 4nilotinib 3fludarabine 3bosutinib 3asciminib 3Sirolimus 3Mycophenolic Acid 3Cyclophosphamide 3Blood Specimen Collection 3obinutuzumab 2Pentostatin 2Oxycodone 2Naloxone 2KW-2478 2Filgrastim 2Alemtuzumab 2ziconotide 1sodium luminolate 1posaconazole 1ponatinib 1pegfilgrastim 1oblimersen 1montelukast 1mocetinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bronchiolitis Obliterans Syndrome × ixekizumab × Clear all
NCT01107457 2019-09-24

A Study in Participants With Moderate to Severe Psoriasis

Eli Lilly and Company

Phase 2 Completed
142 enrolled 45 charts
Lymphoid

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Psoriasis, Plaque, Amyloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡